Chris Meekins

Chris Meekins, an analyst at FBR, was a guest on CNBC's "Halftime Report" segment on Wednesday and offered three reasons why pharmaceutical investors should brush off President-elect Donald Trump's comments that he is "going to bring down drug prices." 3 Reasons First, Meekins argued what is more...